TD Cowen Sticks to Its Hold Rating for Milestone Pharmaceuticals (MIST)
TD Cowen analyst Ritu Baral maintained a Hold rating on Milestone Pharmaceuticals today. The company’s shares closed last Friday at $1.56.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Alnylam Pharma, and ACADIA Pharmaceuticals. According to TipRanks, Baral has an average return of 9.2% and a 47.66% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Milestone Pharmaceuticals with a $5.00 average price target.
The company has a one-year high of $2.75 and a one-year low of $0.63. Currently, Milestone Pharmaceuticals has an average volume of 1.39M.
Read More on MIST:
Disclaimer & DisclosureReport an Issue
- Milestone Pharmaceuticals Announces Public Offering for $48.7M
- Why Is Milestone Pharmaceuticals Stock (MIST) Down 30% Today?
- Milestone prices $52.5M common shares offering at $1.50 per share
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Milestone Pharmaceuticals Amends Royalty Agreement with RTW
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.